Firstly, it seems you have a very weak understanding on statistic. I don't know how well you did in your pharmacy course, but even a high school student can tell 10 people for a trials is statistically insignificant. You may argue it's just a interim report, but my point is such interim report is meaningless if they are not statistically significant. Applying your concept, if I just pick 3 people undergo a trial and do an INTERIM report, do you think that report actually means anything meaningful?
Secondly, nurofen and paracetamol is a general analgesic and is the first-line for treating fever/pain associated with COVID-19. It is laughable for a pharmacist to recommend a natural supplement that have no substantial evidence, over something that proven to be working. It is a bit like you are recommending a patient suffering from acute UTI taking Cranberry supplement, instead of antibiotics such as Cephalexin or Trimethoprim. (even though there is isolated research shows cranberry MAY BE beneficial in people with UTI)
Thirdly, please stop quoting non-evidence based articles, such as those from Forbes. I hope you remembered your lecturer in Uni taught you to avoid any evidence that may be biased (and for the same reason, pharmacists should avoid using even eMIMS).
Lastly, the rules and regulations about clinical trials are much more relaxed in Israel and India, compared to Australia and Europe. Also, transparency is lacking in this instance as one can't even find the trial ID (or if anyone know the trial ID, it will be much appreciated to share here)
From your argument, it makes me wonder do you complete your pharmacy course in Australia? or from oversea?
- Forums
- ASX - By Stock
- COVID-19 Trial - Supplementary material/Thoughts
Firstly, it seems you have a very weak understanding on...
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
|
|||||
Last
35.0¢ |
Change
0.015(4.48%) |
Mkt cap ! $16.94M |
Open | High | Low | Value | Volume |
34.5¢ | 35.5¢ | 33.0¢ | $60.95K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11855 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 1338 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11855 | 0.270 |
1 | 20000 | 0.250 |
1 | 2200 | 0.230 |
1 | 14600 | 0.205 |
2 | 17358 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 14 | 1 |
0.400 | 6621 | 3 |
0.415 | 225 | 1 |
0.420 | 147 | 2 |
0.430 | 28 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
RGT (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online